PXD	Title	Drug	Cellline/Tissue	Quantification	Disease
PXD003092	Phosphoproteomics analysis of anti-cancer effects of ginsenoside Rg3 in human breast cancer cells	Ginsenoside Rg3	MDA-MB-231	TMT	Breast cancer
PXD003530	Sites of aspirin-mediated lysine acetylation in HeLa cells	Aspirin	HeLa?	LFQ	Cervix carcinoma
PXD006581	Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment	tofacitinib	BMSC	Label free	
PXD014786	A proteomic approach for characterizing trastuzumab-emtansine modified for nuclear directed localization that enhances cytotoxicity identifies regulatory nuclear transport receptor.	"T-DM1,trastuzumab"	SKBR3	Spectrum count/molecular weight	Breast cancer
PXD018929	Novel Aza-Podophyllotoxin Derivative in Triple Negative Breast Cancer	SU212	"MCF10A,MCF12A,MDA-MB-231,MDA-MB-468"	TMT	Breast cancer
PXD019038	Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly-diagnosed glioblastoma	sunitinib	"GBM: U87,U251,T98G and U138 ，HT29 colon cancer as positive ctl"	Label free	Glioblastoma
PXD023569	Cerulenin action on colon cancer cell line	Cerulenin	RW480	Unknown	Colon cancer
PXD031346	Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Phosphotyrosine Profiling	"lorlatinib,cabozantinib,crizotinib,entrectinib"		TMT	Lung cancer
PXD041324	New ruthenium-cyclopentadienyl complexes affect colorectal cancer hallmarks showing high therapeutic potential	"PMC79,PMC78,LCR134 and CR220"	RW480	label-free	Colorectal cancer
PXD041686	Transcriptome and proteome analysis reveals the anti-cancer properties of Hypnea musciformis macroalgae extract in liver and intestinal cancer cells	Hypnea musciformis extract(algae extract)	liver cancer cellline HepG2 and colon cancer cellline LS174	label-free	"Liver cancer,Colon cancer"
PXD043359	Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression	Bergenin	Cervical cancer cells		Cervical cancer
PXD043585	MIB/MS determines SCH772984 is a selective ERK1/2 inhibitor in pancreatic cancer cells	SCH772984	"SW 1990,MIA PaCa-2,PANC-1,HPAC,AsPC-1,Panc 10.05"	label-free	Pancreatic cancer
PXD044042	Phosphoproteomic analysis of Aurora Kinase B inhibition in WT and Cdh1 mutant RPE1 cells	Barasertib	RPE1	TMT	Retinal pigment epithelium
PXD045777	Multilevel Plasticity and Altered Glycosylation Drive Aggressiveness in Hypoxic and Glucose-Deprived Bladder Cancer Cells	glucose deprivation(Cisplatin)	"RT4,5637,T24 和 HT1197(choose T24,5637)"	Label free	Bladder cancer
PXD047335	ANDROGEN DRIVES MELANOMA INVASIVENESS AND METASTATIC SPREAD BY INDUCING TUMORIGENIC FUCOSYLATION: Phosphoproteomics	ARi	melanoma cells	TIC	Melanocyte
PXD048479	Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition	"Vemurafenib,dasatinib"	M397	TMT	Melanoma
PXD048534	The ERK-dependent proteome is enriched in the mouse PDAC KPC RAS-dependent phosphoproteome	RMC7977	"K8484,K18905"	TMT	Pancreatic ductal adenocarcinoma
PXD049299	A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of ImidazoCPyrazole Treatment in SKMEL-28 Melanoma Cells	Imidazopyrazole 衍生物CB556	SKMEL-28	Label free	Skin cancer
PXD050555	TMT-10plex-based phosphoproteomics of bioactive compounds in A549 cells	"Chamuangone, Cannabigerol (CBG), Cannabidiol (CBD), NP1-cyclic peptide"	A549	TMT	NSCLC
PXD051299	Polydopamine nanoparticles-based hyperthermal chemotherapy for the treatment of liver cancer	Sorafenib	HepG2	Unknown	Unknown
PXD051376	Unlocking Selective Anticancer?Mechanisms: Dinuclear Manganese Superoxide Dismutase Mimetics Combined with Pt(II) Complexes	"Mn2L2Ac,Mn2L2,PtDAPCl2，Mn2L2Pt"	"MCF 10A,MCF 7"	MS1 intensity based label-free quantification method	Breast cancer
PXD052305	A549 treated with CISPLATIN/TSA VS CONTROL	"CISPLATIN,TSA"	A549	TMT	Colon cancer
PXD052364	Impact of Aldehyde Dehydrogenase Inhibition on the Stemness of Endometrial Cancer Stem Cells	DEAB	"ECC-1 , RL95-2"	TIC	Cervix carcinoma
PXD000065	HiRIEF deep proteomics of A431 human vulvar cancer cell line and N2A mouse neuroblastoma cell line	Gefitinib	"A431 human cell line, mouse N2A cell line"	iTRAQ8plex	Epidermoid Carcinoma
PXD000681	Probing tyrosine kinase inhibitors specificity	"HDAC 抑制剂,SAHA"	A431		Squamous cell carcinoma
PXD000861	"Phosphopattern Predicts CK2 Substrate, HMGA1, as a Drug Resistant Target for Non-Small Cell Lung Cancer"	Gefitinib	"PC9,PC9/gef,BEAS-2B"	Label free	Lung cancer
PXD001101	Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics	erlotinib	"H3255,H1975?"	SILAC	Lung adenocarcinoma
PXD001812	Phosphoproteomic analysis of tamoxifen resistant breast cancer	Tamoxifen	"MCF7,MCF7-CTRL,MCF7-TamR"	SILAC	Breast cancer
PXD003655	Half-lives of aspirin-mediated lysine acetylations	Aspirin	HeLa	SILAC	Cervix carcinoma
PXD003790	HLA peptides (LC-MSMS) induced by Decitabine in Glioblastoma cell lines	Decitabine	"U-87,T98G,LNT-229"	Label free	Glioblastoma
PXD004541	CETSA proteomics to investigate drug binding in BJ Ras Sv40 cells treated with MTH1 inhibitors.	TH1579	BJ Ras Sv40	TMT	Breast cancer
PXD004941	Integrative analysis of proteome and ubiquitylome reveals unique features of protein ubiquitylation and mitochondria in gefitinib resistant non-small cell lung cancer cells	Gefitinib	NSCLC cells PC9/GR (gefitinib-resistant) and PC9 (gefitinib-sensitive)	SILAC	Lung cancer
PXD004995	"Sites of aspirin-mediated lysine acetylation in HeLa cells, part 2"	Aspirin	HeLa	SILAC	Cervix carcinoma
PXD005514	"TUMOUR KINOME RE-WIRING GOVERNS RESISTANCE TO PALBOCICLIB IN OESTROGEN RECEPTOR POSITIVE BREAST CANCERS, HIGHLIGHTING NEW THERAPEUTIC MODALITIES"	palbociclib	"wt-MCF7,MCF7-LTED"	Unknown	Unknown
PXD005536	Quantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib	"Dasatinib,Pazopanib"	A204?	SILAC	Rhabdoid cancer
PXD006139	Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits Glycogen Synthase Kinase 3 Beta and Activates WNT Signaling	"Abemaciclib,Palbociclib,Trametinib,BMS-777607,Dasatinib"	"H2228,mouse：HEK293T/17"	TMT/label-free	Lung cancer
PXD006459	Human lamin B1: stress-induced phosphorylation	MMS	HCC1937	Label free	Cervix carcinoma
PXD006561	CDK4/6 inhibitor resistance in prostate cancer	palbociclib	"LNCaP,LAPC4"	Unknown	Prostate cancer
PXD006705	Targeting Focal Adhesion Kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of Epidermal Growth Factor Receptor	"erlotinib,PF-562271,dasatinib"	"H358,H1299 and H1650"	SILAC	Non-small cell lung carcinoma
PXD006732	Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements	"Tamoxifen,N-Desmethyl Tamoxifen"	MCF-7	SILAC	Breast cancer
PXD006915	"The proteome alterations associated with treatment with Photodynamic Therapy, endosomes after Bleomycine-mediated photochemical internalization on rat bladder cancer cells"	Bleomycin，Bleomycin + fimaporfin (photosensitizer)	AY-27?	SILAC	Urinary bladder cancer
PXD007256	"Calcium/calmodulin dependent protein kinase kinase 2 (CAMKK2), an alternative to curcumin in head and neck squamous cell carcinoma."	Curcumin	CAL 27	SILAC	Oral cavity cancer
PXD007740	A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells	"BRAFi,EGFRi"	"WiDr,WiDr PTPN11 KO"	unknown	Colon cancer
PXD007769	SILAC-based quantitative tyrosine phosphoproteomic profiling identifies alternative therapeutic targets to erlotinib in head and neck squamous cell carcinoma	erlotinib	"HNSCC,SCC-R,SCC-S"	SILAC	head and neck squamous cell carcinoma
PXD008032	Differential activity of treatment with protein kinase inhibitors on tumor phosphotyrosine profiles in patients with advanced cancer	"carfilzomib,bortezomib,melphalan,E7107,KH-CB19,TG003,zVAD-fmk,lenalidomide,Venetoclax"	"The experimental group consisted of patients, and the control group consisted of HCT116."	TMT	"Hepatocellular carcinoma
Pancreatic cancer
Colon cancer
Melanoma
Esophageal cancer
Prostate cancer
Kidney cancer"
PXD008454	Adaptive resistance to Afatinib in non-small cell lung cancer cells in attenuated by Ca2+ depletion	"Afatinib,Gefitinib"	"PC9,H1975,HCC827,H1650?"	"Label free

SILAC"	Non-small cell lung carcinoma
PXD009041	Functional proteomics of midostaurin in lung cancer cells: IMAC Phosphoproteomics	midostaurin	Lung cancer cell lines	TIC	Lung cancer
PXD010786	Functional proteomics of midostaurin in lung cancer cells: IMAC Phosphoproteomics	Midostaurin	Lung cancer cell lines	TMT	Lung cancer
PXD012172	Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma	HBX41108	"MDA - MB - 231,MDA - MB - 468,MCF10A"	"Label free

SILAC"	Multiple myeloma
PXD012963	Divergent polypharmacology-driven cellular activity of structurally similar multi-kinase inhibitors through cumulative differential effects on individual targets: IMAC Phosphoproteomics	"Foretinib,Cabozantinib"	H1155	TMT	Lung cancer
PXD013859	XPO1 is a critical player for Bortezomib resistance in Multiple Myeloma: A quantitative proteomic approach	bortezomib	"RPMI 8226,RPMI 8226 - R"	Label Free	Multiple myeloma
PXD015751	Cellular interactome dynamics during paclitaxel treatment	paclitaxel	HeLa	SILAC	Cervix carcinoma
PXD016475	Integrating phenotypic search and phosphoproteomic profiling of active kinases for optimization of drug mixtures for renal cell carcinoma treatment	"Das,Erl,Axi,combi Das-Erl-Axi"	786-O	label-free	Renal cell carcinoma
PXD016604	Optimized high-order drug mixtures improve colorectal carcinoma treatment via inactivationof MAP kinase signaling pathway and cell cycle alteration	PR-619	U2OS	Label free	Colon cancer
PXD019999	p53 C-terminal acetylation modulates apoptotic program	"Irinotecan,MS-275(Entinostat)"	Isogenic p53-positive and -negative CRC cells	Parallel Reaction Monitoring (PRM)	Colon cancer
PXD020108	Global proteome and phosphoproteome alterations in 3rd generation EGFR TKI resistance reveal drug targets to circumvent resistance	"Osimertinib,Rociletinib"	"H1975,AZR3/AZR4,COR1/COR10"	SILAC	Lung cancer
PXD020590	LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma	"ORY-1001,GSK-LSD1"	Merkel cell carcinoma (MCC) cell line	TMT	Skin cancer
PXD021265	Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma	lenalidomide	Multiple myeloma patient source	TMT	Multiple myeloma
PXD022164	Indisulam targets RNA splicing and metabolism to serve as a novel therapeutic strategy for high-risk neuroblastoma	Indisulam	Neuroblastoma cell line	TIC	Colon cancer
PXD022982	Inhibition of the Histone Deacetylase activity impacts on Glioblastoma secretome and disrupts the molecular signature of the Tumor Extracellular Matrix	Trichostatin A	U87MG GBM	unknown	Glioblastoma
PXD024910	Quantitative proteomics analysis reveals novel insights into mechanisms of action of Disulfiram (DSF)	Disulfiram	HeLa	SILAC	Cervix carcinoma
PXD024965	Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Potential Targets for Cancer Immunotherapy	"Abemaciclib,Palbociclib"	"MCF7,T47D"	Unknown	Breast cancer
PXD025481	Single cell chemical proteomics (SCCP) interrogates the timing and heterogeneity of cancer cell commitment to death	"Methotrexate (MTX),Camptothecin (CPT),Tomudex (TDX)"	A549	TMT	Lung adenocarcinoma
PXD028125	A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells	MCI-INI-3	GSCs	TIC	Brain cancer
PXD029296	Exploring the mechanism of action of Canmei formula against colorectal adenoma through multi-omics technique	"Canmei formula,sulfasalazine"	mouse	TMT	Stage iv colorectal cancer
PXD029586	Analysis of protein secretome of human hepatocellular carcinoma (HCC) Cancer Associated Fibroblasts (CAFs) after long term (14 days) treatment with Transforming Growth Factor beta 1 (TGF beta 1)	TGF beta 1	CAFs	Unknown	Hepatocellular carcinoma
PXD031295	Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer ImmunotherapyRepurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy	MMR vaccine	"Hepa 1-6,Hep3B"	label-free	Hepatocellular carcinoma
PXD031359	Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Phosphoproteomics	"lorlatinib,cabozantinib,crizotinib,entrectinib,Defactinib,GSK2256098,PND - 1186,Saracatinib,Bosutinib"	"HCC78,CUTO2,CUTO28,CUTO23,CUTO27,CUTO33"	TMT	Lung cancer
PXD031690	Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Chemical Proteomics	"lorlatinib,cabozantinib,crizotinib,entrectinib,Defactinib,GSK2256098,PND - 1186,Saracatinib,Bosutinib"	"HCC78,CUTO2,CUTO28,CUTO23,CUTO27,CUTO33"	TIC	Lung cancer
PXD033956	Phosphoproteomics of BYL719 (alpelisib)-Resistant T47D Human Breast Cancer Cell Line	Alpelisib (BYL719)	T47D	label-free	Breast cancer
PXD036341	Trib3 modulates PPAR?-mediated growth inhibition by interfering with the MLL complex in breast cancer cells	Trib3?Kinase	MCF7 	SILAC	Breast cancer
PXD036716	Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib	brigatinib	CUTO9	TIC	Lung cancer
PXD036771	Mig6 mediates adaptive and acquired resistance to ALK and ROS1 fusion kinase inhibition through feedback activation of EGFR: Cuto28	"ALK/ROS1 抑制剂,Afatinib,Crizotinib，Entrectinib"	ROS1	TMT	Lung cancer
PXD040496	Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition	"rapamycin,bortezomib"	"?HeLa,786-O"	TMT	renal cell carcinoma
PXD042004	TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting pro-survival autophagy	bortezomib	"RPMI8226-Luc,U266"	Unknown	multiple myeloma
PXD042498	Total Proteome: Ergolide Mediates Anti-Cancer Effects on Metastatic Uveal Melanoma Cells and Modulates their Cell Lysate and Extracellular Vesicle proteomes.	Ergolide	OMM2.5	Label free	Uveal melanoma
PXD043220	Proteomic and phosphoproteomic reprogramming in epithelial ovarian cancer metastasis	Y-27632	"OVCAR8,HeyA8"	TMT	Malignant neoplasm of ovary
PXD043514	Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics	sunitinib	HCT116	Label free	Kidney
PXD044543无文献有结果	A small molecule targeting NMHC IIA phosphorylation exerts promising anti-tumor effects on colorectal cancer	LS-1-2	"HCT116,HCT8"	TMT/iTRAQ	Colorectal cancer (CRC)
PXD045779	Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA	dTAG-13	"HEK293,HEK293-FT"	TMT	Epithelial cell
PXD046446	Proteomic and phosphoproteomic analysis of ESR1 mutant cells	"EtOH,E2"	MCF7	TMT	breast cancer
PXD046734	Phosphoprotein dynamics of interacting tumor and T cells by HySic	NVS-PAK1-1	"A549,EBC-1,G358,LCLC"	"SILAC,label-free"	Non-small cell lung carcinoma
PXD046822	"1,4-dihydroxy Quininib Activates Ferroptosis Pathways in Metastatic Uveal Melanoma and Reveals a Novel Prognostic Biomarker Signature"	"1,4-dihydroxy Quininib"	OMM2.5	Label free	Uveal melanoma
PXD046871	Temporal Quantitative Phosphoproteomic Profiling of SH-SY5Y and IMR-32 Neuroblastoma Cells During All-trans Retinoic Acid-Induced Neuronal Differentiation	ATRA	"SH-SY5Y,IMR-32"	TMT	Neuroblastoma
PXD046900	Temporal Quantitative Proteomic Profiling of SH-SY5Y and IMR-32 Neuroblastoma Cells During All-trans Retinoic Acid-Induced Neuronal Differentiation	ATRA	"SH-SY5Y,IMR-32"	TMT	Neuroblastoma
PXD047837	ATM Inhibition Exploits Checkpoint Defects and ATM-Dependent Double Strand Break Repair in TP53-Mutant Glioblastoma	"temozolomide,AZD1390"	TP53-mutant GBM	TMT	Glioblastoma
PXD048277	Rebound after MAPK inhibitor withdrawal in pLGG cells	"Dabrafenib,Trametinib,Vincristine,Carboplatin,Alpelisip,Ipatasertib"	"BT-40,HMC3,DKFZ-BT66,DKFZ-BT308,DKFZ-BT314"	unknown	Brain cancer
PXD048529	The ERK-dependent phosphoproteome in KRAS mutant pancreatic cancer	SCH772984	"MIA PaCa-2,PANC-1,HPAC,Panc 10.05,ASPC-1 and SW1990"	TMT	Pancreatic ductal carcinoma
PXD048531	The ERK-dependent proteome in KRAS mutant pancreatic cancer	SCH772984	"MIA PaCa-2,PANC-1,HPAC,Panc 10.05,ASPC-1 and SW1990"	Label free	Pancreatic ductal adenocarcinoma
PXD048532	The ERK-dependent phosphoproteome is enrciched in KRAS G12C dependent phosphoproteome	"MRTX1257,SCH772984"	"H358,SW837, MIA PaCa-2"	TMT	"Pancreatic ductal adenocarcinoma
Non-small cell lung carcinoma
Colorectal cancer"
PXD048695	L-Glyceraldehyde inhibits neuroblastoma cell 1 growth via a multi-modal mechanism on metabolism 2 and signaling	Glyceraldehyde (GA)	"IMR-32,SH-SY5Y,VH7"	Label free	neuroblastoma
PXD049123	Phosphoproteomics of Hela cells stimulated with EGF in the presence of protein phosphatase inhibitors	"Raphin1 acetate, sanguinarine chloride, KY-226, SHP099, NSC95397,BCI"	Hela	Label free	ov 
PXD050260	The effect of an MLK3-targeting PROTAC on protein levels in model breast cancer cell lines.	CEP1347-VHL-02 PROTAC	"MCF-7,MDA-MB-468,HCC1806"	TMT	Breast cancer
PXD050987	FAS Inhibited Proteomics and Phosphoproteomics Profiling of Colorectal Cancer Spheroids shows Activation of Ferroptotic Death Mechanism	"Cerulenin,TVB-2640"	"HT-29,HCT 116"	Normalized Spectral Abundance Factor - NSAF	Colon cancer
PXD051094	SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and Ipatasertib Kinase Inhibitors	"Ipatasertib,Lapatinib"	SKBR3	Spectrum counting	Breast cancer
PXD051199	Development of novel chemical inhibitors of SETD8	C23 and C110 compound(SETD8 inhibitor)	U2OS	TMT	Osteosarcoma
PXD052203	A549 cell treated with DDP+TSA vs DDP	"TSA,DDP"	A549	TMT	Colon cancer
PXD052259	Phosphoproteomics of BRAFi-treated endothelial cells	"Vemurafenib, Dabrafenib, Encorafenib, PLX8394"	donor	TMT	Melanoma
PXD052657	A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer	"Doxo,LXG6403"	"MDA - MB - 231,HCC1937,Hs - 578 - T,HCC1143"	matrix-assisted laser desorption-ionisation imaging mass spectrometry	Breast cancer
PXD053902	Integrated proteomic and global phosphoproteomic analysis of cisplatin-induced apoptosis in A549 cells	cisplatin	A549	Label free	Lung cancer
PXD054180	Lapatinib-Induced Enhancement Of Mitochondrial Respiration In HER2-Positive SK-BR-3 Cells: Mechanism Revealed By Analysis Of Proteomic But Not Transcriptomic Data	Lapatinib	SK-BR-3	Label free	Breast cancer
PXD055164	Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer	"cisplatin,silmitasertib"	CaSki	TMT	Cervix carcinoma
PXD056197	"IMPRINTS-CETSA Alpelisib and Buparlisib in MCF-7 cells, 6h incubation"	"Alpelisib,Buparlisib"	MCF-7	TMT	Unknown
